Economic impact of 13‐valent pneumococcal conjugate vaccine in Finnish adults ≥50 years with underlying chronic medical conditions

By  

JOURNAL OF EVALUATION IN CLINICAL PRACTICE (ELECTRONIC), Vol. 20, Iss. 4, 2014-08 ,pp. : 333-341

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden

By Bergman Annika   Hjelmgren Jonas   Ortqvist Åke   Wisløff Torbjørn   Sønbø Kristiansen Ivar   Diaz Hogberg Liselotte   M-S Persson Kristina   Persson Ulf  

Scandinavian Journal of Infectious Diseases, Vol. 40, Iss. 9, 2008-01 ,pp. : 721-729

Informa Healthcare

Access to resources Recommend Favorite

Serotype replacement of Streptococcus pneumoniae due to seven‐valent pneumococcal conjugate vaccine in Japan

By  

PEDIATRICS INTERNATIONAL, Vol. 60, Iss. 1, 2018-01 ,pp. : 52-56

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adverse Reactions to Pneumococcal Vaccine in Pediatric and Adolescent Patients with Sickle Cell Disease

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 35, Iss. 7, 2015-07 ,pp. : 696-700

John Wiley & Sons Inc

Access to resources Recommend Favorite

10‐valent pneumococcal non‐typeable Haemophilus influenzae protein‐D conjugate vaccine (PHiD‐CV) induces memory B cell responses in healthy Kenyan toddlers

By  

CLINICAL & EXPERIMENTAL IMMUNOLOGY, Vol. 181, Iss. 2, 2015-08 ,pp. : 297-305

John Wiley & Sons Inc

Access to resources Recommend Favorite